Lenalid 5 Capsule contains Lenalidomide 5 mg, an immunomodulatory agent indicated primarily for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts its therapeutic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is commonly prescribed as part of combination therapy or as monotherapy depending on the specific hematologic malignancy and patient profile. The capsule formulation allows for oral administration, facilitating ease of use and adherence to prescribed regimens. Dosage and duration of treatment should be individualized based on disease severity, patient tolerance, and response to therapy, with careful monitoring for potential adverse effects such as neutropenia, thrombocytopenia, and thromboembolic events. Lenalid 5 Capsule is contraindicated in pregnancy due to its teratogenic potential and requires strict adherence to risk management programs to prevent fetal exposure. Regular blood counts and clinical assessments are essential to detect hematologic toxicity early. Patients should be advised regarding possible side effects, including fatigue, rash, and gastrointestinal disturbances, and instructed to report any unusual symptoms promptly. Lenalid 5 Capsule should be stored as per manufacturer guidelines and used under strict medical supervision to optimize therapeutic outcomes and minimize risks.